Focused On-demand Library for Transient receptor potential cation channel subfamily M member 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q7Z4N2

UPID:

TRPM1_HUMAN

Alternative names:

Long transient receptor potential channel 1; Melastatin-1

Alternative UPACC:

Q7Z4N2; D9IDV2; D9IDV3; F8W865; H0YN37; O75560; Q6PE48; Q7Z4N1; Q7Z4N3; Q7Z4N4; Q7Z4N5

Background:

Transient receptor potential cation channel subfamily M member 1 (TRPM1), also known as Melastatin-1, plays a crucial role in cellular processes by mediating the influx of divalent cations, including Na(2+), Ca(2+), and Mg(2+). This channel's activity is essential for the depolarizing photoresponse in retinal ON bipolar cells, highlighting its significance in visual function.

Therapeutic significance:

TRPM1's involvement in congenital stationary night blindness underscores its therapeutic potential. Understanding TRPM1's function could pave the way for innovative treatments for visual impairments and contribute to strategies aimed at retinal disorder management.